See "Qualified therapies in CLL: mechanisms of resistance and strategies for management" on webpage 471. Duvelisib was the 2nd PI3K inhibitor permitted by the FDA, also according to a stage III randomized trial.a hundred thirty The efficacy and basic safety profile with the drug appear similar with These of idelalisib, https://napoleonr531krz7.blogadvize.com/profile